Relay Therapeutics, Inc. (RLAY) Misses Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Join SI Premium – FREE
Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $733.33 thousand.
For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top Wealth Group expects net profit to double in fiscal 2026
- McDonald's sets 2030 financial targets with new growth strategy
- Agi names Rafael Siqueira as chief technology officer
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
